Heart disease is the leading cause of death worldwide. Within decades a limited process of cardiac cell regeneration was under observation. Embryonic stem cell (ESC) shows great potential for cell and tissue regeneration. Studies indicate that ESC has the potential to enhance myocardial perfusion and/or contractile performance in ischemic myocardium. However there is still challenge to evaluate the issues of teratoma. Then induced pluripotent stem cell was invented by introducing four transcriptional factors (Oct4, Sox2, Klf4,. iPSC was created from murine fibroblast and then differentiated into cardiomyocyte. Reprogramming the adult cell could be performed in full, partial or direct reprogramming. Several studies add the significance by reprogramming the cells through more efficient techniques. However several limitations are still remained.
Introduction
Heart disease in the form of ischemic heart disease and heart failure is the leading cause of death worldwide, with estimated >7 million death in 2012.
1 Recent treatment strategy is to augment cardiac reperfusion so that can improve patient outcome and reduce morbidity due to heart failure, yet showing various efficacies.
2 The loss of cardiac tissue diminish the properties of the heart to contract normally. 3 The limited ability of human heart to regenerate, thus "regenerative medicine" represents as an alternative "second generation" treatment for ischemic heart disease. 4 This approach may encompass cardiomyocyte regeneration, neovascularization, and paracrine cytokines. 3 Adult heart is dominated by fibroblast and less population of cardiomyocyte. During a cardiac event or injury, fibroblast activation leads to fibrosis, which contribute to heart failure or conduction abnormalities. 5 Transplantation of different cells has been proposed to augment cardiac regeneration. The introduction of MyoD gene in fibroblast stimulated trans-differentiation into skeletal muscle.
2 More recent work on cardiomyocyte regeneration has focused on cell originated from pluripotent embryonic stem cell (ESC) 6 or induced pluripotent stem C e l l a n d
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cell (iPSC) 7, 8 and adult progenitor cell located in the heart termed as resident cardiac progenitor cells (CPC) or in non cardiac-sites (non-resident CPC).
This review will discuss various cardiac cell reprogramming, initially iPSC, a method to reprogram somatic cell into pluripotent stem cell, 7 then partial reprogramming through CPC, 9 and direct reprogramming method which aim to directly convert the mature (unipotent) fibroblast to cardiomyocyte without going through iPSC type. 10 Furthermore we will discuss the benefit and future use of cardiac reprogramming in heart disease.
Cardiomyocyte regeneration
Several vertebrae like axolotl, 11 zebrafish and newt,
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are evident to have significant regeneration capacity of the heart. This ability is also found transiently in mice during the first week of their live. 13 Shortly after birth, human myocardium growth transition from hyperplastic to hypertrophic phase, characterized by the presence of binucleated cardiomyocyte. Indicating the cardiomyocyte differentiation already terminated.
14 However this concept has been changed recently, 14 C was used to carbon date the DNA of proliferating cardiomyocyte. Limited regeneration of human cardiomyocyte from pre-existing cardiomyocyte was confirmed, approximately 1% per year and 0.4% per year at age 20 and 75 respectively. 15 A similar rate of cardiogenesis in young human adults was recently confirmed (1.9% at 20 years) and declined after 20 years old with the loss of cytokinetic ability. 16 Based on this, about 45% would be renewed over the normal human lifespan and more significance in woman compare to male population, 15 to 11 times cardiomyocyte turnover respectively.
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Cardiopoesis and self-generating cells
The natural response for cardiac tissue damage is reinforcement of stem cells programming to lineagespecifying cardiovascular-derived defined as cardiopoiesis.
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Cardiopoiesis guides stem cells to re-activate cellular plasticity, re-engage into cardiovasculogenesis, and re-set an active propensity for repair. Many type of stem cells already tested to measure their ability to regenerate: adult cells (umbilical cord blood mononuclear cell, [19] [20] [21] bone marrowderived mesenchymal stem cell, 22, 23 resident or endogenous cardiac stem cell, 24 endothelial progenitor cell [25] [26] [27] [28] ); and ESC or iPSC which shows great potentials. 7, 29 Preliminary studies indicate that ESC has the potential to enhance myocardial perfusion and/or contractile performance in ischemic myocardium. However there is still challenge to evaluate the issues of teratoma 22 and what actually drives the improvement of cardiac function after the application ESC. 30 In the other hand to maintain cardiopoesis, small molecules in the form of growth factors or cytokines such as fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), erythropoietin (EPO) or granulocyte colony stimulating factor (G-CSF) also introduced to enhance the mobilization of progenitor cells.
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Novel cell sources "cardiomyocyte from ESC or iPSC" ESC is undiffentiated, pluripotent and self-renewing cell in appropriate culture condition, which give rise to three embryonic germ layers. The gene expression of ESCderived cardiomyocyte resembles mammalian heart and become mature with time. 31 In order to reduce immune graft rejection, generation of allogeneic patient-specific cells are warranted.
A novel approach with four transcription factors 2,32 Generatedcardiomyocte can be cultivated ex-vivo than transplanted into infarcted tissue or induction of cardiomyocyte in vivo with various recognized transcription factors or microRNA (miR).
Full reprogramming
ESC is known to reliably give rise to cardiomyocyte in vitro. This pluripotent cell can be propagated in undiffentiated state and then coaxed to variety of cell lineages. 33 Nevertheless, the inability to create patient-or disease-specific ESC from adult individual and immune rejection-associated with allogeneic cell transplant raise the limitation when translated to clinical use.
The introduction of four transcription factors 7, 34 become the major revolution in regenerative medicine. This strategy required full reprogramming of fibroblasts into iPSCs, and subsequent differentiation to cardiomyocyte, which take a long period (months). Functional analyses of iPSC-derived cardiomyocyte demonstrate that they are embryonic or immature cardiomyocyte rather than adult type cardiomyocyte. 32 At present cardiomyocyte derived from human iPSC is used for disease modeling.
Partial reprogramming
One of the limitations in using the iPSC approach is the duration, which may take a few months to complete the processes including fibroblast expansion and reprogramming, expanding the generated iPSC colonies, and finally differentiate into the cardiac lineage. 7 To overcome this limitation, overexpression of Oct4, Sox2, and Klf4, c-Myc in murine fibroblast was performed in short incubation period with cardio-inductive medium by adding growth factor bone morphogenetic protein (BMP)4 and an inhibitor of Janus kinase (JAK) to further prevent development of pluripotent lineage. 9 Using this strategy cardiomyocyte generation can be shortened within 11-12 days. However, it is still unrevealed how the partially reprogrammed cardiomyocyte compare with those derived from pluripotent stem cell lines, in terms of their cardiomyocyte phenotypic properties and their capacity for cardiac repair.
Direct reprogramming
Direct reprogramming fibroblast into induced cardiomyocyte (iCM) can be performed by adding some combination of gene specific transcription factors (Gata4, Mef2c, Tbx5, Hand2, Myocd, etc.) into cardiac fibroblast, tail tip fibroblast (TTF) or mouse embryonic fibroblast (MEF). These transcription factors were introduced using viral vectors (retroviruses, lentiviruses, adenoviruses, etc.); or lipofection method to transfect cells with cardiac specific miR. 32 iCM can be produced by adding a combination of three developmental transcription factors (Gata4, Mef2c, Tbx5) 10 or four transcription factors (Gata4, Mef2c, Hand2, Tbx5). 35 However evaluation to suitable iCM is still remained a challenge. Interestingly, combination of Mef2c, Tbx5, Myocd, resulted in a more developed cardiomyocyte. 36 When translated in vivo, the application of Gata4, Mef2c, Tbx5 in vivo in 2 month infarcted mice using retroviral, showed a decreased infarct size and improvement in cardiac function. 37 Transduction with retroviruses contain four transcription factors Gata4, Hand2, Mef2c Tbx5 to cardiac fibroblast in vivo showed an increase of iCM like cell (9.2%), almost 4-fold higher compared with Gata4, Mef2c, Tbx5 (2.5%). 35 In addition, in vivo iCMs express more fully reprogrammed than their in vitro counterparts, suggest an unrevealed factors that enhance reprogramming. 35, 37 The potential of miR for differentiating pluripotent stem cells to cardiovascular lineage was recognized. 38 By introducing miR (miR-1, miR-133, miR-208, and miR-499) into neonatal cardiac fibroblasts, iCMs could be resulted directly in vitro and in vivo. Application of miR was enhanced by JAK inhibitor treatment. The miR-mediated induction found to be safer for applications in humans. 39 Compared with Gata4, Mef2c, Tbx5 merely, miR and Gata4, Mef2c, Tbx5 combination produce 7-fold beating iCMs and shorten the duration in inducing beating cells. 40 
From translational research to human application in vivo
There were three studies in direct reprogramming of fibroblasts. [41] [42] [43] Combination of four transcription factors (Gata4, Hand2, Tbx5, and Myocd) and two muscle-specific miRs (miR-1 and miR-133), could reprogram up to 20% of fibroblast into cTnT + cells. Furthermore, a subset of iCMs demonstrated spontaneous beating after 11 weeks in culture. 43 Similarly, a mixture of seven transcription factors (Gata4, Mef2c, Tbx5, Mesp1, Myocd, Zfpm2, . 32 (Adapted with permission from International Heart Journal). 41 Besides all stated transcription factor, ETS-2 was also used in combination with Mesp1 for fibroblast treated with activin A and BMP2 to reprogram human dermal fibroblasts into cardiac progenitor-like cells, which can differentiate into iCMs. 44 Despite these promising features, direct cardiac reprogramming is less efficient in human cells compared to murine fibroblasts. An optimized combination of appropriate transcription factors and miRs for direct human cardiac reprogramming is required, as well as preconditioning for human cardiomyocyte.
Future issues and challenges
Reprogramming process though promising still lead with several limitations especially in terms of teratoma formation, 32 differentiation efficiency, the specificity of cardiomyocyte phenotype, 34 long term survival of the cells and immune graft rejection. 45 Many factors are yet to be revealed in favor to generate efficient reprogramming. Applying hypoxic environment or directly introduce in vivo are reported to increase the possibility of new cardiomyocyte. 46 Further research and validation of methods are necessary.
Conclusion
Through full, partial or direct reprogramming, adult cardiomyocyte can be generated in vitro or in vivo by adding several transcriptional factors. Many limitation considered regarding most efficient and standardization of protocols before translated to clinical practice.
